Ascelia Pharma AB (publ) Asset Resilience Ratio
Ascelia Pharma AB (publ) asset resilience ratio. Ascelia Pharma AB (publ) (ACE) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Ascelia Pharma AB (publ) fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ascelia Pharma AB (publ) (2016–2023)
Asset resilience ratio of Ascelia Pharma AB (publ) from 2016 to 2023. This chart shows how Ascelia Pharma AB (publ)'s Asset Resilience Ratio has changed over time. Read Ascelia Pharma AB (publ) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ascelia Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ascelia Pharma AB (publ) balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ascelia Pharma AB (publ) maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ascelia Pharma AB (publ) Industry Peers by Asset Resilience Ratio
Compare Ascelia Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Ascelia Pharma AB (publ) Asset Resilience Ratio by Year (2016–2023)
Ascelia Pharma AB (publ) asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Ascelia Pharma AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | Skr1.00K ≈ $107.62 |
Skr87.07 Million ≈ $9.37 Million |
-- |
| 2020-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr255.37 Million ≈ $27.48 Million |
-- |
| 2019-12-31 | 30.26% | Skr75.71 Million ≈ $8.15 Million |
Skr250.23 Million ≈ $26.93 Million |
+4.14pp |
| 2018-12-31 | 26.12% | Skr75.08 Million ≈ $8.08 Million |
Skr287.42 Million ≈ $30.93 Million |
+26.18pp |
| 2016-12-31 | -0.06% | Skr-47.00K ≈ $-5.06K |
Skr80.39 Million ≈ $8.65 Million |
-- |
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more